Floatz logo

CYTARABINE

Down Syndrome

Federal Research Institute of Pediatric Hematology, Oncology and ImmunologySmall moleculePhase 3Active
BB
67/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
53/ 100
Competitive Position
95/ 100

Competitive context

33 Active assets in the Down Syndrome cohort.

Asset / SponsorPhaseRating
VINCRISTINE SULFATE
National Cancer Institute (NCI)
Phase 3BB
PEGASPARGASE
National Cancer Institute (NCI)
Phase 3BB
MERCAPTOPURINE ANHYDROUS
National Cancer Institute (NCI)
Phase 3BB
METHOTREXATE
National Cancer Institute (NCI)
Phase 3BB
ASPARAGINASE
National Hospital Organization Nagoya Medical Center
Phase 3BB

View all 35 →

Same molecule, other indications

CYTARABINE is also rated in:

acute promyelocytic leukemiaActive
A
Indicative · Phase 4
82 / 100
View asset →
adult acute lymphoblastic leukemiaActive
BBB
Indicative · Phase 4
79 / 100
View asset →
acute myeloblastic leukemia with maturationDormant
BBB
Indicative · Phase 3
78 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →